SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.
Preclinical 3D Study models for oncology and neurology.
MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.
4D Lifetest™ is our flagship product and the first non-invasive CE IVD certified blood liquid biopsy assay to assess cancer formation due to its unique transformational biomarker at its earliest stage. This diagnostic information enables eraly invention and is a breakthrough progress to reduce mortality rates of cancer patients and protect benign patients from the invasive stress of frequently repeated surveillance diagnostics.The assay is CE IVD certified for the early detection of lung, breast, prostate and colon cancer and comercially available via our commercialization partner Medicover.